ACADIA Pharmaceuticals Inc. (ACAD) |
|
18.24 -0.08 (-0.44%)
|
03-24 16:00 |
|
Open: |
18.21 |
Pre. Close: |
18.32 |
|
High:
|
18.305 |
Low:
|
17.925 |
|
Volume:
|
1,390,019 |
Market Cap:
|
2,959(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:23:44 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 23.78  One year: 25.54 |
| Support: |
Support1: 17.92 Support2: 14.91 |
| Resistance: |
Resistance1: 20.36 Resistance2: 21.87 |
| Pivot: |
19.79 |
| Moving Average: |
MA(5): 18.85 MA(20): 19.93
MA(100): 17.46  MA(250): 17.37 |
| MACD: |
MACD(12,26): -0.2 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 6.1 %D(3): 12.9 |
| RSI: |
RSI(14): 39.1 |
| 52-week: |
High: 28.05 Low: 12.23 |
| Average Vol(K): |
3-Month: 1,560 (K) 10-Days: 2,508 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ACAD ] has closed above bottom band by 3.2%. Bollinger Bands are 46% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
18.42 - 18.6 |
18.6 - 18.71 |
|
Low:
|
17.55 - 17.78 |
17.78 - 17.92 |
|
Close:
|
17.97 - 18.35 |
18.35 - 18.58 |
|
Company Description |
|
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California. |
Headline News |
Sun, 26 Mar 2023
Analysts have given ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ... - Best Stocks
Mon, 20 Mar 2023
ACADIA Pharmaceuticals Inc (ACAD) Down 1.72% in Premarket Trading - InvestorsObserver
Sun, 19 Mar 2023
Validea's Top Ten Healthcare Stocks Based On Kenneth Fisher - 3 ... - Nasdaq
Tue, 14 Mar 2023
Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts ... - Benzinga
Mon, 13 Mar 2023
Is ACADIA Pharmaceuticals Inc (ACAD) Stock About to Get Hot Monday? - InvestorsObserver
Fri, 10 Mar 2023
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
162 (M) |
| Shares Float |
120 (M) |
|
% Held by Insiders
|
0.2 (%) |
|
% Held by Institutions
|
97.7 (%) |
|
Shares Short
|
8,040 (K) |
|
Shares Short P.Month
|
8,100 (K) |
Stock Financials |
|
EPS
|
-1.3 |
|
EPS Est Next Qtl
|
-0.63 |
|
EPS Est This Year
|
-2.55 |
|
EPS Est Next Year
|
-1.97 |
|
Book Value (p.s.)
|
2.47 |
|
Profit Margin (%)
|
-41.8 |
|
Operating Margin (%)
|
-43.3 |
|
Return on Assets (ttm)
|
-21.8 |
|
Return on Equity (ttm)
|
-45.9 |
|
Qtrly Rev. Growth
|
4.4 |
|
Gross Profit (p.s.)
|
0.89 |
|
Sales Per Share
|
3.18 |
|
EBITDA (p.s.)
|
-1.37 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-114 (M) |
|
Levered Free Cash Flow
|
-35 (M) |
Stock Valuations |
|
PE Ratio
|
-14.04 |
|
PEG Ratio
|
-1.8 |
|
Price to Book value
|
7.38 |
|
Price to Sales
|
5.72 |
|
Price to Cash Flow
|
-25.95 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
